Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1

PURPOSE: In MONARCH 1 (NCT02102490), single-agent abemaciclib demonstrated promising efficacy activity and tolerability in a population of heavily pretreated women with refractory HR+, HER2− metastatic breast cancer (MBC). To help interpret these results and put in clinical context, we compared over...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res Treat
Autors principals: Rugo, Hope S., Dieras, Veronique, Cortes, Javier, Patt, Debra, Wildiers, Hans, O’Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A., Carter, Gebra Cuyun, Sheffield, Kristin M., Li, Li, Andre, Valerie A. M., Li, Xiaohong I., Frenzel, Martin, Huang, Yu-Jing, Dickler, Maura N., Tolaney, Sara M.
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2020
Matèries:
Clinical Trial
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7568708/
https://ncbi.nlm.nih.gov/pubmed/32789591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05838-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars